Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese

British Journal of Clinical Pharmacology

Volumn 60, Issue 6, 2005, Pages 629-631

  Luo, Chen Hui ^a   Wang, An ^a   Zhu, Rong Hua ^a   Zhang, Wei Xia ^a   Mo, Wei ^a   Yu, Bang Ning ^a   Chen, Guo Lin ^a   Ou Yang, Dong Sheng ^a   Duan, Xiao Hong ^a   Abd El Aty, A M ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP2C9; Gender; Hyperlipidaemia

Indexed keywords

CYTOCHROME P450 2C9;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEX RATIO;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEX CHARACTERISTICS;

EID: 28244455819     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02498.x     Document Type: Article

References (12)

1. O'Brien T, Nguyen TT. Lipids and lipoproteins in women. Mayo Clin Proc 1997; 72: 235-44.
2. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging 2002; 19: 169-78.
3. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH. Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin 2001; 22: 148-54.
4. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998; 11: 659-65.
5. Goldstein JA. Polymorphisms in the human CYP2C subfamily. Drug Metabolism Rev 2002; 34(Suppl 1): 5.
6. Xie HG, Prasad H, Landau R, et al. Frequency of the Defective CYP 2C9 variant alleles in different ethnic groups [abstract]. Clin Pharmacol Ther 2002; 71: P102.
7. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 18: 1257-70.
8. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405-9.
9. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 803-8.
10. Soucek P, Sarmanova J, Kristensen VN, Apltauerova M, Gut I. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Int Arch Occup Environ Health 2002; 75 (Suppl): S86-92.
11. (2A) receptor gene polymorphism, T102C and essential hypertension. J Hum Hypertens 2001; 15: 335-9.
12. Jockenhovel F, Bullmann C, Schubert M, et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999; 48: 590-6.